Abstract:IntroductionMutations in the FUS gene have been shown to be a rare cause of amyotrophic lateral sclerosis (ALS-FUS) and whilst well documented clinically and genetically there have been relatively few neuropathological studies.Recent work suggested a possible correlation between pathological features such as frequency of basophilic inclusions in neurons and rate of clinical decline, other studies have revealed a discrepancy between the upper motor neuron features detected clinically and the associated pathology. The purpose of this study was to describe the pathological features associated with more recently discovered FUS mutations and reinvestigate those with well recognised mutations in an attempt to correlate the pathology with mutation and/or clinical phenotype. The brains and spinal cords of seven cases of ALS-FUS were examined neuropathologically, including cases with the newly described p.K510E mutation and a case with both a known p.P525L mutation in the FUS gene and a truncating p.Y374X mutation in the TARDBP gene.ResultsThe neuropathology in all cases revealed basophilic and FUS inclusions in the cord. The density and type of inclusions varied markedly between cases, but did not allow a clear correlation with clinical progression. Only one case showed significant motor cortical pathology despite the upper motor neuron clinical features being evident in 4 patients. The case with both a FUS and TARDBP mutation revealed FUS positive inclusions but no TDP-43 pathology. Instead there were unusual p62 positive, FUS negative neuronal and glial inclusions as well as dot-like neurites.ConclusionsThe study confirms cases of ALS-FUS to be mainly a lower motor neuron disease and to have pathology that does not appear to neatly correlate with clinical features or genetics. Furthermore, the case with both a FUS and TARDBP mutation reveals an intriguing pathological profile which at least in part involves a very unusual staining pattern for the ubiquitin-binding protein p62.

Animal Models of FUS-Proteinopathy: A Systematic Review

From Mouse Models to Human Disease: An Approach for Amyotrophic Lateral Sclerosis

In Vitro Models of Amyotrophic Lateral Sclerosis

Multiple lines of evidence for disruption of nuclear lamina and nucleoporins in FUS amyotrophic lateral sclerosis

Antisense oligonucleotide silencing of FUS expression as a therapeutic approach in amyotrophic lateral sclerosis

Neuromuscular dysfunction in patient-derived FUS -ALS iPSC model via axonal downregulation of neuromuscular junction proteins

Synaptic accumulation of FUS triggers age-dependent misregulation of inhibitory synapses in ALS-FUS mice

Mutations in FUS lead to synaptic dysregulation in ALS-iPSC derived neurons

Cytoplasmic aggregation of mutant FUS causes multistep RNA splicing perturbations in the course of motor neuron pathology

Pathological insights from amyotrophic lateral sclerosis animal models: comparisons, limitations, and challenges

The usage and advantages of several common amyotrophic lateral sclerosis animal models

Modeling sporadic juvenile ALS in iPSC-derived motor neurons explores the pathogenesis of FUSR503fs mutation

Aberrant Phase Separation of FUS Leads to Lysosome Sequestering and Acidification

Prion-Like Propagation of Protein Misfolding and Aggregation in Amyotrophic Lateral Sclerosis

The Fused in Sarcoma Protein Forms Cytoplasmic Aggregates in Motor Neurons Derived from Integration-Free Induced Pluripotent Stem Cells Generated from a Patient with Familial Amyotrophic Lateral Sclerosis Carrying the FUS-P525L Mutation

Promising animal models for amyotrophic lateral sclerosis drug discovery: a comprehensive update

Therapeutic tools for familial ALS

Murine experimental models of amyotrophic lateral sclerosis: an update

New developments in pre-clinical models of ALS to guide translation

ALS-FUS pathology revisited: singleton FUS mutations and an unusual case with both a FUS and TARDBP mutation

Targeting FUS-ALS aggregation with Proteasome Inhibitors